Navigation Links
Mindray Medical International Announces First Quarter 2008 Results
Date:5/7/2008

SHENZHEN, China, May 7 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices in China with a rapidly growing international presence, today announced its selected unaudited financial results for the first quarter ended March 31, 2008.

Highlights for First Quarter 2008

-- First quarter 2008 net revenues were RMB626.0 million (US$89.3 million),

an increase of 48.2% over from RMB422.4 million (US$54.7 million) in

the first quarter 2007.

-- Net revenues generated in international markets in the first quarter

2008 were RMB319.6 million (US$45.6 million), an increase of 49.4% from

RMB213.9 million (US$27.7 million) in the first quarter 2007.

-- Net revenues generated in China in the first quarter 2008 were

RMB306.4 million (US$43.7 million), an increase of 46.9% from RMB208.5

million (US$27.0 million) in the first quarter 2007.

-- Non-GAAP operating profit, as defined below, in the first quarter 2008

was RMB220.5 million (US$31.4 million), a 54.6% increase from RMB142.6

million (US$18.5 million) in the first quarter 2007. First quarter 2008

GAAP operating profit was RMB199.8 million (US$28.5 million).

-- First quarter 2008 non-GAAP net income, as defined below, was RMB199.2

million (US$28.4 million), an increase of 42.7% from RMB139.6 million

(US$18.1 million) in the first quarter 2007. First quarter 2008 GAAP net

income was RMB179.4 million (US$25.6 million).

-- First quarter 2008 non-GAAP diluted earnings per share, as defined

below, was RMB1.76 (US$0.25) compared to RMB1.25 (US$0.16) in tngs per share. Each of the terms as used by the Company is defined as follows:
-- Non-GAAP gross profit represents gross profit reported in accordance

with GAAP, adjusted for the effects of share-based compensation, and

expense and/or amortization of acquired intangible assets.

-- Non-GAAP operating profit represents operating profit reported in

accordance with GAAP, adjusted for the effects of share-based

compensation, and expense and/or amortization of acquired intangible

assets including, but not limited to, in-progress research and

development (IPR&D).

-- Non-GAAP net income represents net income reported in accordance with

GAAP, adjusted for the effects of share-based compensation, and expense

and/or amortization of acquired intangible assets including, but not

limited to, IPR&D, all net of related tax impact.

-- Non-GAAP earnings per share represents non-GAAP net income divided by

the number of shares used in computing basic and diluted earnings per

share in accordance with GAAP, and excludes the impact of the deemed

dividends for the basic calculation.

In addition to Mindray's consolidated financial results under GAAP, the Company also provides non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating profit, non-GAAP net income and non-GAAP earnings per share on a basic and fully diluted basis. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Mindray's financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing Mindray's underlying business performance and operating trends and the Company expects to report operating profit and net income on a non-GAAP basis using a consistent method on a quarterly basis going forward.

The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three-month periods ended March 31, 2007 and 2008, respectively, in the attached financial statements.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" including those related to the Company's anticipated operating results for 2008, the anticipated timing for closing the Datascope transaction and the corresponding impact on the Company's operating results, and the Company's anticipated effective tax rate. These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. In addition, the Datascope transaction may not close when anticipated or at all. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: the expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F, filed on June 26, 2007. Our results of operations for the first quarter of 2008 and for fiscal year 2008 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

This announcement contains translations of certain Renminbi amounts into US dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the quarters ended March 31, 2008, March 31, 2007, and December 31, 2007 were made at the noon buying rate in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserve Bank of New York, or the noon buying rate, as of March 31, 2008, March 30, 2007, and December 31, 2007 which was RMB7.0120, RMB7.7232, and RMB7.2946 to US$1.00, respectively, unless noted otherwise. Mindray makes no representation that the Renminbi or US dollar amounts referred to in this release could have been or could be converted into US dollars or Renminbi, as the case may be, at any particular rate or at all.

All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

The accounting policies underlying the financial information for the segmental reporting are based primarily on statutory accounting requirements in the PRC.

Exhibit 1

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

As at

December 31,

2007 As at March 31, 2008

RMB RMB US$

(unaudited) (unaudited)(unaudited)

ASSETS (In thousands) (In thousands)

Current assets:

Cash and cash equivalents 1,379,009 1,486,983 212,063

Short-term investments 407,744 658,244 93,874

Accounts receivable, net 210,176 234,473 33,439

Inventories 181,022 202,418 28,867

Value added tax receivables 238 60 9

Other receivables 39,155 43,131 6,151

Prepayments and other 14,009 19,783 2,821

Deferred tax assets - current

portion 4,400 3,550 506

Total current assets 2,235,753 2,648,642 377,730

Loans to employees 4,366 3,876 553

Long-term investments 250,000 -- --

Other assets 15,294 15,291 2,181

Advance for purchase of plant

and equipment 132,053 152,332 21,724

Property, plant and equipment,

net 350,551 406,407 57,959

Land use right 17,764 17,731 2,529

Intangible assets, net 130,649 125,942 17,961

Goodwill 122,169 122,169 17,423

Total assets 3,258,599 3,492,390 498,059

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Notes payable 63,460 62,508 8,914

Accounts payable 132,820 148,757 21,215

Advance from customers 52,696 61,583 8,783

Salaries payables 60,857 33,707 4,807

Other payables 124,661 283,849 40,480

Income taxes payable 56,246 82,190 11,721

Other taxes payable 14,801 13,547 1,932

Total current liabilities 505,541 686,141 97,852

Advance from customers -- 14,003 1,997

Minority interests 11 11 2

Deferred tax liabilities, net 24,699 23,751 3,387

24,710 37,765 5,386

Shareholders' equity:

Ordinary shares 111 111 16

Additional paid-in capital 2,062,361 2,083,314 297,107

Retained earnings 737,596 778,932 111,086

Accumulated other comprehensive

loss (71,720) (93,873) (13,387)

Total shareholders' equity 2,728,348 2,768,484 394,821

Total liabilities and shareholders'

equity 3,258,599 3,492,390 498,059

(1) All translations from Renminbi to US dollars as of and for the quarter

ended March 31, 2008 were made at the noon buying rate of the Federal

Reserve Bank of New York as of March 31, 2008, which was RMB7.012 to

US$1.00

Exhibit 2

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended March 31,

2007 2008 2008

RMB RMB US$

(unaudited) (unaudited) (unaudited)

(In thousands, except share

and per share data)

Net revenues

- PRC 208,543 306,388 43,695

- International 213,866 319,605 45,580

Net revenues 422,409 625,993 89,275

Cost of revenues (note 2) (185,282) (272,101) (38,805)

Gross profit 237,127 353,892 50,469

Selling expenses (note 2) (48,050) (75,065) (10,705)

General and administrative

expenses (note 2) (23,168) (18,720) (2,670)

Research and development

expenses (note 2) (41,265) (60,304) (8,600)

Other general expenses (37) (44) (6)

Operating income 124,607 199,759 28,488

Other income, net 3,164 3,596 513

Interest income 17,560 16,884 2,408

Interest expense (96) (35) (5)

Income before income taxes and

minority interests 145,235 220,204 31,404

Provision for income taxes (22,866) (40,837) (5,824)

Minority interests -- -- --

Net Income 122,369 179,367 25,580

Basic earnings per share 1.16 1.68 0.24

Diluted earnings per share 1.09 1.59 0.23

Shares used in the computation

of:

Basic earnings per share 105,743,984 106,962,659 106,962,659

Diluted earnings per share 111,869,215 112,998,260 112,998,260

(2) Share-based compensation

charges incurred during the

period related to:

Cost of revenues 349 789 113

Selling expenses 4,892 5,767 822

General and administrative

expenses 4,022 4,091 583

Research and development

expenses 4,000 5,357 764

Exhibit 3

MINDRAY MEDICAL INTERNATIONAL LIMITED RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST

COMPARABLE GAAP MEASURES

Three months ended March 31,

2007 2008 2008

RMB RMB US$

(unaudited) (unaudited) (unaudited)

(In thousands, except share

and per share data)

Non-GAAP net income (note 3) 139,633 199,231 28,413

Non-GAAP net margin 33.1% 31.8% 31.8%

Expense/Amortization of acquired

intangible assets (4,707) (4,707) (671)

Deferred tax impact related

to acquired intangible

assets 706 847 121

Effect of change in tax rate

on deferred tax -- -- --

Share-based compensation (13,263) (16,004) (2,282)

GAAP net income 122,369 179,367 25,580

GAAP net margin 29.0% 28.7% 28.7%

Non-GAAP income per share

- basic 1.32 1.86 0.27

Non-GAAP income per share

- diluted 1.25 1.76 0.25

GAAP income per share

- basic 1.16 1.68 0.24

GAAP income per share

- diluted 1.09 1.59 0.23

Shares used in computation of:

Basic earnings per share 105,743,984 106,962,659 106,962,659

Diluted earnings per share 111,869,215 112,998,260 112,998,260

Non-GAAP operating income 142,577 220,470 31,442

Non-GAAP operating margin 33.8% 35.2% 35.2%

Expense/Amortization of acquired

intangible assets (4,707) (4,707) (671)

Share-based compensation (13,263) (16,004) (2,282)

GAAP operating income 124,607 199,759 28,488

GAAP operating margin 29.5% 31.9% 31.9%

Non-GAAP gross profit 242,183 359,388 51,253

Non-GAAP gross margin 57.3% 57.4% 57.4%

Expense/Amortization of acquired

intangible assets (4,707) (4,707) (671)

Share-based compensation (349) (789) (113)

GAAP gross profit 237,127 353,892 50,469

GAAP gross margin 56.1% 56.5% 56.5%

For investor and media inquiries please contact:

In China:

Investor Relations

May Li

Mindray Medical International Limited

Tel: +86-755-2658-2518

Email: IR@Mindray.com

Justin Knapp

Ogilvy Public Relations Worldwide, Beijing

Tel: +86-10-8520-6556

Email: Justin.Knapp@Ogilvy.com

In the United States:

Jeremy Bridgman

Ogilvy Public Relations Worldwide, New York

Tel: +1-212-880-5363

he first

quarter 2007. First quarter 2008 GAAP diluted earnings per share was

RMB1.59 (US$0.23). First quarter 2008 income tax expense was RMB40.8

million (US$5.8 million), representing an effective tax rate of 18.5%

compared to a 15.7% effective tax rate in the first quarter 2007, or an

increase of 78.6% from RMB22.9 million (US$3.0 million) in the first

quarter 2007.

-- Mindray provides gross margin, operating margin, net income and

earnings per share on a non-GAAP basis that exclude non-cash, share-

based compensation expense and acquired intangible assets amortization

expense to enable investors to better assess the Company's operating

performance. The non-GAAP measures are described below and reconciled

to the corresponding GAAP measure in the section below titled ''Use of

Non-GAAP Financial Measures.''

''We delivered another quarter of strong results both in China and international markets,'' said Mr. Xu Hang, Mindray's chairman and co-chief executive officer. ''During the quarter, we successfully acquired Datascope Corporation's patient monitoring business, bringing us one step closer to our goal of becoming a leading global medical device provider, which will allow us to make high-quality and affordable medical devices available to the greatest number of doctors and hospitals in China and in the world.''

The Company develops and manufactures over 40 products which are available in more than 140 countries.

''Despite a challenging currency environment, we achieved high growth in international markets that was widespread across geographies and well balanced between product segments while maintaining a high gross margin,'' added Mr. Li Xiting, Mindray's president and co-chief executive officer. "In our home market, we delivered more than 40 percent growth in sales for the fourth consecutive quarter. With a world-class R&D team and strict capital discipline, we continued to drive down costs and enhance overall operating efficiency to achieve higher year-over-year growth in our operating profit than in revenues during the quarter.''

Financial Results for First Quarter 2008

Mindray reported net revenues of RMB626.0 million (US$89.3 million) for the first quarter 2008, a 48.2% increase from RMB422.4 million (US$54.7 million) in the first quarter 2007.

Net revenues generated in international markets in the first quarter 2008 increased 49.4% to RMB319.6 million (US$45.6 million) from RMB213.9 million (US$27.7 million) in the first quarter 2007.

Net revenues generated in China in the first quarter 2008 increased 46.9% to RMB306.4 million (US$43.7 million) from RMB208.5 million (US$27.0 million) in the first quarter 2007.

Performance by Segment

Patient Monitoring & Life Support Products: Patient monitoring & life support products segment revenues increased 30.2% to RMB208.9 million (US$29.8 million) from RMB160.5 million (US$20.8 million) in the first quarter 2007. The patient monitoring & life support products segment contributed 33.9% to total net segment revenues in the first quarter 2008.

In-Vitro Diagnostic Products: In-vitro diagnostic products segment revenues increased 56.1% to RMB208.7 million (US$29.8 million) from RMB133.7 million (US$17.3 million) in the first quarter 2007. The in-vitro diagnostic products segment contributed 33.9% to total net segment revenues in the first quarter 2008.

Medical Imaging Systems: Medical imaging systems segment revenues increased 61.2% to RMB189.1 million (US$27.0 million) from RMB117.3 million (US$15.2 million) in the first quarter 2007. The medical imaging systems segment contributed 30.7% to total net segment revenues in the first quarter 2008.

Gross Margins

First quarter 2008 non-GAAP gross profit, as defined below, was RMB359.4 million (US$51.3 million), a 48.4% increase from RMB242.2 million (US$31.4 million) in the first quarter 2007. Non-GAAP gross margin was 57.4% in the first quarter 2008 compared to 57.3% in the first quarter 2007 and 53.8% in the fourth quarter 2007. First quarter 2008 GAAP gross profit was RMB353.9 million (US$50.5 million) compared to RMB237.1 million (US$30.7 million) in the first quarter 2007.

Operating Expenses

Non-GAAP selling expenses for the first quarter 2008 were RMB69.3 million (US$9.9 million), or 11.1% of total net revenues, compared to 10.2% in the first quarter 2007 and 13.8% in the fourth quarter 2007. GAAP selling expenses for the first quarter 2008 were RMB75.1 million (US$10.7 million).

Non-GAAP general and administrative expenses for the first quarter 2008 were RMB14.6 million (US$2.1 million), or 2.3% of total net revenues, compared to 4.5% in the first quarter 2007 and 3.2% in the fourth quarter 2007. GAAP general and administrative expenses for the first quarter 2008 were RMB18.7 million (US$2.7 million).

Non-GAAP research and development expenses for the first quarter 2008 were RMB54.9 million (US$7.8 million), or 8.8% of total net revenues, compared to 8.8% of total net revenues in the first quarter 2007 and 9.1% in the fourth quarter 2007. GAAP research and development expenses for the first quarter 2008 were RMB60.3 million (US$8.6 million).

Total share-based compensation expenses, which were allocated to cost of goods sold and related operating expenses, were RMB16.0 million (US$2.3 million) in the first quarter 2008, compared to RMB13.3 million (US$1.7 million) in the first quarter 2007 and RMB17.5 million (US$2.4 million) in the fourth quarter 2007.

Non-GAAP operating profit, as defined below, in the first quarter 2008 was RMB220.5 million (US$31.4 million), a 54.6% increase from RMB142.6 million (US$18.5 million) in the first quarter 2007. Non-GAAP operating margins were 35.2% in the first quarter 2008, compared to 33.8% in the first quarter 2007 and 27.6% in the fourth quarter 2007. GAAP operating profit in the first quarter 2008 was RMB199.8 million (US$28.5 million) compared to RMB124.6 million (US$16.1 million) in the first quarter 2007.

Net Income

First quarter 2008 non-GAAP net income increased 42.7% year-over-year to RMB199.2 million (US$28.4 million) from RMB139.6 million (US$18.1 million) in the first quarter 2007. Non-GAAP net margins were 31.8% in the first quarter 2008, compared to 33.1% in the first quarter 2007 and 27.5% in the fourth quarter 2007. First quarter 2008 GAAP net income was RMB179.4 million (US$25.6 million) compared to RMB122.4 million (US$15.8 million) in the first quarter 2007. First quarter 2008 income tax expense was RMB40.8 million (US$5.8 million), representing an effective tax rate of 18.5% compared to a 15.7% effective tax rate in the first quarter 2007, or an increase of 78.6% from RMB22.9 million (US$3.0 million) in the first quarter 2007.

First quarter 2008 basic and diluted non-GAAP earnings per share were RMB1.86 (US$0.27) and RMB1.76 (US$0.25), respectively. First quarter 2007 basic and diluted non-GAAP earnings per share were RMB1.32 (US$0.17) and RMB1.25 (US$0.16), respectively. First quarter 2008 GAAP basic and diluted earnings per share were RMB1.68 (US$0.24) and RMB1.59 (US$0.23), respectively. First quarter 2007 GAAP basic and diluted earnings per share were RMB1.16 (US$0.15) and RMB1.09 (US$0.14), respectively. Shares used in the computation of diluted earnings per share increased from 111.9 million in the first quarter 2007 to 113.0 million in the first quarter 2008 due to issuances of new shares and grants of share options in the past twelve months.

The China Unified Corporate Income Tax Law (the "New Law") became effective on January 1, 2008. The New Law established a single unified 25% income tax rate for most companies with some preferential income tax rates including a 15% income tax rate to be applicable to qualified ''New and Hi- Tech Enterprises.'' The related detailed implementation rules and regulations on the definition of various terms and the interpretation and application of the provisions of the New Law were promulgated by the State Council in December 2007. While the implementation guide for the ''New and Hi-Tech Enterprises'' was promulgated on April 14, 2008, the New Law is pending for implementation by the relevant government authorities. The Company expects that it will apply and shall qualify for the "New and High-Tech Enterprise" status that will allow it a 15% income tax rate under China's Unified Enterprise Income Tax Law. Under applicable accounting rules, until the Company receives official approval for this status, it must use the transition rule in its calculation of its deferred tax balances as well as its income tax, which means a gradual increase in rates over the five-year transition period. If the Company had received the approval prior to March 31, 2008, its first quarter 2008 net income would have increased by RMB5.7 million for deferred tax balances and by RMB6.9 million for income tax applicable to its Shenzhen subsidiary using the 15% tax rate. This amount of accrued income taxes will be reversed as soon as the Company receives official approval for the ''New and Hi-Tech Enterprise'' status.

Other Select Data

Average accounts receivable days outstanding was 32 days for the first quarter 2008 compared to 22 days for the first quarter 2007 and 26 days for the full year 2007. Inventory turnover was 64 days for the first quarter 2008 compared to 72 days for the first quarter 2007 and 55 days for the full year 2007. Average accounts payable days outstanding was 68 days for the first quarter 2008 compared to 75 days for the first quarter 2007 and 59 days for the full year 2007.

As of March 31, 2008, the Company had RMB2,145.2 million (US$305.9 million) in cash and cash equivalents and short-term investments. Net cash generated from operating activities and capital expenditures for the first quarter 2008 were RMB218.7 million (US$31.2 million) and RMB68.8 million (US$9.8 million), respectively.

As of March 31, 2008 the Company had 4,050 employees compared to 3,705 employees on December 31, 2007.

Business Outlook for Full Year 2008

In March 2008, Mindray agreed to acquire Datascope Corporation's (Nasdaq: DSCP) patient monitoring business for approximately $202 million in cash (the ''Datascope acquisition'' or the ''transaction''). The transaction, expected to close in mid-May, will create, upon completion, the third-largest player in the global patient monitoring device industry and furthers Mindray's goal of becoming a leading provider of high-quality medical devices to markets worldwide. After closing of the transaction, the Company expects its full-year 2008 net revenue guidance to be in the range of US$560 million to US$580 million, assuming the consolidation of Datascope's patient monitoring business starting from May 1, 2008.

The updated full-year 2008 non-GAAP (excluding share-based compensation expenses and amortization of intangible assets resulting from acquisitions) net income guidance will be in the range of US$132 million to US$135 million, taking into consideration a 15% effective income tax rate after certain government tax incentives and rebates.

Non-GAAP EPS is expected to be in the range of US$1.16 to US$1.18 per fully diluted share based on an estimated average diluted share count of 114 million for the year. Previously issued non-GAAP EPS guidance was in the range of US$1.15 to US$1.17 per fully diluted share (based on Mindray's estimated average forecast foreign exchange rate of RMB7.15 to US$1.00 at the time of issuance). The Company expects the Datascope acquisition to yield a neutral impact to its 2008 non-GAAP EPS.

In accordance with SFAS No. 123R, the Company estimates total share-based compensation expenses in 2008 will be approximately US$11 million based on employee share options that have been granted as of May 7, 2008. The Company expects approximately US$20 million in acquisition-related intangible amortization expenses in 2008 including the April 2006 acquisition of minority interest and the Datascope acquisition, subject to the finalization of the purchase price allocation for the Datascope acquisition.

The Company expects its capital expenditure for 2008 to be in the range of US$90 million to US$110 million.

The Company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

The translation rate of RMB to USD in the business outlook section is based on Mindray's estimated average forecast foreign exchange rate, which is RMB6.725 to US$1.00.

Change in Reporting Currency to the U.S. Dollar

Effective April 1, 2008, Mindray changed its reporting currency to the U.S. Dollar (US$). Mindray will report its consolidated financials in U.S. Dollars (US$) starting from its second quarter 2008 results. The change in reporting currency will (1) more accurately reflect Mindray's increased global operations following the closing of the Datascope acquisition and (2) improve investors' comprehension of Mindray's financial results and ability to compare with other companies internationally. Prior to March 31, 2008, the Company's annual and quarterly financial statements and notes were prepared and reported in Renminbi (RMB). The Company will provide financial results for periods prior to March 31, 2008, restated to reflect the US$ as the reporting currency for comparison to the financial results for the quarters ended March 31, 2007, June 30, 2007, March 31, 2008 and June 30, 2008, and for the year ended December 31, 2007, with the announcement of its second quarter 2008 financial results.

Conference Call Information

Mindray's management will hold an earnings conference call at 8:00 a.m. on May 8, 2008 U.S. Eastern Time (8:00 p.m. on May 8, 2008 Beijing/Hong Kong Time).
Dial-in details for the earnings conference call are as follows:

Hong Kong: +852-3002-1672

US Toll Free: +1-800-706-7748

International: +1-617-614-3473

Passcode for all regions: Mindray A replay of the conference call may be accessed by phone at the following numbers until May 19, 2008.

US Toll Free: +1-888-286-8010

International: +1-617-801-6888

Passcode: 61704457

Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://www.mindray.com .

About Mindray

Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices in China with a significant and growing presence worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products, and medical imaging systems. Mindray is headquartered in Shenzhen, China, and has 29 local sales and service offices in China, as well as sales and service offices in Amsterdam, Moscow, Istanbul, London, Mexico City, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .

Use of Non-GAAP Financial Measures

The Company has reported (1) for the first quarter 2008 non-GAAP net income, operating income, and earnings per share on a non-GAAP basis and (2) for the estimated full year 2008 non-GAAP net income and earni
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
2. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
3. Mindray Medical International Announces Third Quarter 2007 Results
4. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
8. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
11. ATS Medical Expands Open Pivot Heart Valve Offerings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis ... Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, ... market is expected to reach USD 2.20 Billion by 2021 from ... the forecast period. Continue Reading ... ...
(Date:12/8/2016)... La Jolla, CA (PRWEB) , ... December 08, 2016 , ... ... that 2016 was a banner year for team building events, new program offerings and ... focus, which it expanded earlier this year to include groups of over 30 people. ...
(Date:12/8/2016)... India , December 8, 2016 ... a comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market Research ... classification, application, and industry chain overview are all covered in ... SWOT analysis, and investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment of ... President of Eurofins Scientific Inc. (ESI). Mr. Murray ... proven professional and entrepreneurial experience in leading international business teams. As ... food testing market to uphold Eurofins, status as the global leader ... , ...
Breaking Biology Technology:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):